Reduced expression of <scp>TRIM</scp>21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease

Abstract

We show that loss of TRIM21 expression is associated with more aggressive lymphoma and increased proliferation, whereas maintenance of TRIM21 expression is associated with better prognosis in patients with DLBCL. Based on our findings, we suggest that TRIM21 should be considered as a novel biomarker for lymphoma characterization and for predicting patient survival.